RTW Investments, a hedge fund specializing in life sciences with $6.5 billion in assets, is currently being investigated by the Securities and Exchange Commission (SEC) for its involvement in a proxy fight at Masimo Corp.
The SEC inquiry is being cooperatively addressed by RTW Investments, as they have assured their clients that it is merely a fact-finding effort and does not indicate any wrongdoing.
This investigation serves as a reminder of the ongoing scrutiny faced by hedge funds and their role in corporate governance matters.